SCHEMBL5229829

SCHEMBL5229829

CCOC(=O)C1CCN(Cc2ccc(-c3nc4c(C)nn(-c5ccccc5)c4c(=O)[nH]3)c(OC)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 5/20 0.52
MAPT P10636 1/20 0.49
PDE5A O76074 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
CCR8 P51685 1/20 0.46
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PDE7A Q13946 1/20 0.44
PDE7B Q9NP56 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230195 0.93 PDE7A (0.46) ALDH1A1KDM4EPDE5AHDAC1HDAC6
SCHEMBL5230917 0.89 PDE7A (0.47) PDE5AHDAC1HDAC6PDE7APDE7B
SCHEMBL5227959 0.86 PDE7A (0.48) PDE5AHDAC1HDAC6PDE7APDE7B
SCHEMBL5228424 0.86 PDE7A (0.63) ALDH1A1KDM4EPDE5AHDAC1HDAC6
SCHEMBL5228443 0.85 PDE7A (0.46) PDE5AHDAC1HDAC6PDE7APDE7B
SCHEMBL5229865 0.85 PDE7A (0.41) KDM4EPDE5AHDAC1HDAC6PDE7A
SCHEMBL5228107 0.84 PDE7A (0.45) ALDH1A1KDM4EPDE5APDE7APDE7B
SCHEMBL5230096 0.81 PDE7A (0.47) PDE7APDE7B
SCHEMBL5237338 0.79 PDE7A (0.50) MAPTPDE5AHDAC1HDAC6PDE7A
SCHEMBL5228314 0.79 PDE7A (0.65) PDE7APDE7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A ALDH1A1 711/4885KDM4E 2235/4885MAPT 4356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.